Q3 EPS Estimate for Promis Neurosciences Lifted by Analyst

Key Points

• HC Wainwright raised Promis Neurosciences’ Q3 2026 EPS estimate to a loss of $0.98 per share from a previous loss estimate of $1.13, while maintaining a “Buy” rating.
• Promis reported a Q2 loss of $1.28 per share, beating consensus estimates by $0.10. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $34.00.
• PMN shares opened at $8.66, well below their 12-month high of $27.40, while institutional investors and hedge funds own approximately 50.13% of the stock.

Promis Neurosciences (NASDAQ:PMN - Free Report) - Analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of Promis Neurosciences in a note issued to investors on Monday, October 12th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.98) per share for the quarter, up from their previous estimate of ($1.13). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Promis Neurosciences' current full-year earnings is ($5.29) per share. HC Wainwright also issued estimates for Promis Neurosciences' Q4 2026 earnings at ($0.86) EPS, FY2026 earnings at ($4.18) EPS, Q1 2027 earnings at ($0.68) EPS, Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.71) EPS and FY2027 earnings at ($2.63) EPS.

Promis Neurosciences (NASDAQ:PMN - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.38) by $0.10.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald began coverage on Promis Neurosciences in a research note on Tuesday, June 30th. They set an "overweight" rating on the stock. Guggenheim reiterated a "buy" rating and set a $69.00 price target (up from $35.00) on shares of Promis Neurosciences in a research report on Tuesday, July 28th. Roth Capital set a $29.00 price target on Promis Neurosciences in a research note on Friday, August 21st. Weiss Ratings reissued a "sell (e+)" rating on shares of Promis Neurosciences in a report on Tuesday, September 8th. Finally, Chardan Capital set a $20.00 price target on Promis Neurosciences and gave the company a "buy" rating in a report on Monday, July 27th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $34.00.

Promis Neurosciences Price Performance

Shares of PMN stock opened at $8.66 on Wednesday. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $27.40. The business has a 50 day simple moving average of $12.78 and a 200 day simple moving average of $12.13.

Institutional Trading of Promis Neurosciences

A number of institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC bought a new stake in Promis Neurosciences during the first quarter worth approximately $16,418,000. Yu Fan acquired a new stake in Promis Neurosciences in the first quarter worth approximately $4,188,000. Ally Bridge Group NY LLC boosted its stake in Promis Neurosciences by 66.1% during the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company's stock valued at $5,261,000 after purchasing an additional 164,880 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Promis Neurosciences during the 1st quarter valued at $1,211,000. Finally, Seven Fleet Capital Management LP bought a new position in Promis Neurosciences during the 1st quarter valued at $135,000. 50.13% of the stock is owned by institutional investors and hedge funds.

About Promis Neurosciences

ProMIS Neurosciences Inc NASDAQ: PMN is a clinical-stage biotechnology company focused on developing antibody-based treatments for neurodegenerative diseases. The company uses its proprietary technology platform to identify disease-related misfolded proteins and selectively target toxic forms that may contribute to neuronal damage.

ProMIS's lead investigational product is PMN310, an antibody designed to target toxic soluble amyloid-beta oligomers associated with Alzheimer's disease while avoiding healthier forms of amyloid-beta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.